CliffBio
biologic

Datroway

datopotamab deruxtecan-dlnk

Loss of exclusivity—loss of exclusivity
CompanyDaiichi Sankyo →See this company's full patent-cliff portfolio

Drug detail

Brand nameDatroway
Active ingredientdatopotamab deruxtecan-dlnk
Strength100MG
Dosage formInjection
RouteIntravenous
ModalityBiologic
Marketing statusRx

More from Daiichi Sankyo

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.